News Veraxa says delayed US listing is back on track Swiss biotech Veraxa's listing on the Nasdaq, delayed by the record 43-day US government shutdown, should now complete in the first quarter of 2026.
News Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.
News UK's Claret Capital raises €575m for European biotechs London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.